KDMN

CLOVIQUE™ (Trientine Hydrochloride Capsules, USP)

Wilson's disease

Stage (next event)

Expected Date

Quarterly Sales (Approved)

March 05, 2021 (Est)

Catalyst Info & Data Links

TITLE: CLOVIQUE™  in Wilson's disease - Quarterly Sales (Approved)


WHAT IS THE CATALYST EVENT?

  • Quarterly sales


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • March 05, 2021 (Est)


PRIOR DATA/EVENTS

PRESS RELEASE

Mechanism of Action

MECHANISM OF ACTION

  • CLOVIQUETM (trientine hydrochloride) is a chelating agent indicated for treatment of patients with WD who are intolerant of the first-line treatment, penicillamine (Learn more HERE). 

MARKET

  • Wilson's disease (WD), the most common inherited disorder of copper metabolism, results from a failure of the copper excretory pathway. This leads to toxic accumulation of copper in the liver and eventually other organs.1 The worldwide prevalence of WD is estimated to be one in 30,000 individuals (Learn more HERE). 

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon